Glancy Prongay & Murray Announces the Filing of a Securities Class Action on Behalf of Mylan N.V. Investors and
Encourages Investors to Contact the Firm
Glancy Prongay & Murray LLP (“GPM”) announces that a class action lawsuit has been filed on behalf of
investors who purchased Mylan N.V. (“Mylan”) or the “Company”) (NASDAQ: MYL) securities between February 21, 2012 and October 5, 2016, inclusive (the “Class Period”). Mylan
investors have until December 12, 2016 to file a lead plaintiff motion.
Investors suffering losses on their Mylan investments are encouraged to contact Lesley Portnoy of GPM to discuss their legal
rights in this class action at 310-201-9150 or by email to shareholders@glancylaw.com.
The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well
as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants made
false and/or misleading statements and/or failed to disclose that: (i) Mylan paid Medicaid significantly lower EpiPen rebates than
legally required; (ii) Medicaid had previously advised Mylan of the Company’s obligation to pay higher rebates; (iii) Mylan
therefore knowingly and systemically overcharged Medicaid for EpiPens in violation of federal law; (iv) millions of dollars of
Mylan’s revenue from EpiPen sales were the result of the foregoing illegal conduct by the Company; and (v) as a result of the
foregoing, Mylan’s public statements were materially false and misleading at all relevant times.
On October 5, 2016, a letter from the Centers for Medicare and Medicaid Services (“CMS”) asserted that Mylan had overcharged the
U.S. Medicaid health program for the Company’s EpiPen shot, despite being told that Mylan needed to provide larger discounts under
the law. The CMS letter stated that from 2011 to 2015, the U.S. Medicaid health program spent approximately $797 million on
EpiPens, including rebates of roughly 13%, rather than the discount of 23.1% that the U.S. should have received. The letter claimed
that the government had “expressly told Mylan that the [EpiPen] product is incorrectly classified.”
If you purchased shares of Mylan during the Class Period you may move the Court no later than December 12,
2016 to ask the Court to appoint you as lead plaintiff if you meet certain legal requirements. To be a member of the Class
you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of
the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your
rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite
2100, Los Angeles California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at http://glancylaw.com. If you inquire by email please include your mailing address, telephone number and number
of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Glancy Prongay and Murray LLP, Los Angeles
Lesley Portnoy, 310-201-9150 or 888-773-9224
https://www.glancylaw.com
shareholders@glancylaw.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20161102006846/en/